The Effect of Treatment With Umbilical Cord Blood Platelet Lysate on Diabetic Foot Ulcers

Last updated: December 2, 2023
Sponsor: Attikon Hospital
Overall Status: Completed

Phase

4

Condition

Ulcers

Diabetes And Hypertension

Treatment

Umbilical cord blood platelel lysate gel

Clinical Study ID

NCT05404295
411/05-06-2019
  • Ages 18-95
  • All Genders

Study Summary

Application of autologous Platelet Rich Plasma (PRP) has been a major breakthrough for the treatment of diabetic foot ulcers, as it provides the necessary growth factors which enhance tissue healing. Human umbilical cord blood platelet lysate (UCB-PL) contains a supraphysiological concentration of growth factors. The aim of the study is to evaluate the efficacy of umbilical cord blood platelet lysate (UCB-PL) gel for the treatment of diabetic foot ulcer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age>18 years old
  • patients with diabetic foot ulcer, foot ulcer located on the plantar, medial, orlateral aspect of the foot (including all toe surfaces)
  • ulcer with area(length x width) measurement<30 cm2
  • non-infected ulcers

Exclusion

Exclusion Criteria:

  • pregnacy
  • venous ulcers
  • clinical signs and symptoms of infection
  • exposure of bone, muscle, ligaments, or tendons and the presence of tunneling

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Umbilical cord blood platelel lysate gel
Phase: 4
Study Start date:
June 10, 2019
Estimated Completion Date:
March 30, 2023

Study Description

110 patients with diabetic foot ulcer will be randomized to receive UCB-PL gel or regular dressing with normal saline. The diabetic foot ulcers will be first debrided to remove any necrotic and infected tissues or hyperkeratotic skin. Afterward, the wound area will be cleaned thoroughly with normal saline. Ulcer length, width and surface will be measured before any study procedure. The UCB-PL gel in the treatment group and the dressing with normal saline in the control group will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area. This will be repeated every three days for one month. After the fist one month of treatment, the patients will be followed up for a period of 20 weeks post-treatment. Care and management efforts will be provided at each visit included cleansing and assessing of the wound, obtaining an interim wound history, including information regarding adverse events, concomitant medications and other aspects of care since the last visit. Ulcers will be photographed at two weeks, at four weeks, at two months, at four months and at six months.

Connect with a study center

  • Catherine Stavropoulos-Giokas

    Athens, Attiki 11527
    Greece

    Site Not Available

  • Vaia Lambadiari

    Athens, Attiki 12462
    Greece

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.